Navigation Links
YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
Date:8/5/2010

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients. To date, 15 patients have been enrolled into the Phase II portion of the study. Given the favourable biological activity and safety data, the Company intends to expand the present program from 60 to 120 patients at up to six centers in the United States, Canada and Australia, subject to regulatory approval. Detailed safety and activity data for CYT387 are planned to be presented at the American Society of Hematology (ASH) meeting in Orlando, Florida in December this year.

Myelofibrosis is a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory due to both efficacy and safety concerns.

Dosing in the Phase I dose-escalation portion of the study commenced in November 2009. In total, 21 patients were treated across five dosing levels (100, 150, 200, 300 and 400mg daily for up to nine months). Reversible, dose-limiting toxicities (DLTs) were observed in two patients at the 400mg dose-level, namely an asymptomatic Grade 3 amylase and lipase elevation and a Grade 3 headache with both patients subsequently resuming treatment with CYT387 at reduced doses.

The m
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... NEW YORK, Sept. 8, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0611079/Global-D-Amino-Acids-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno This ... Acids in US$ Million. The report provides ...
... Sept. 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Metabolomics ... This report analyzes the worldwide ... report provides separate comprehensive analytics for the ...
... a single set of chromosomes for the first time ... The technique should allow scientists to better establish the ... usually contain two sets of chromosomes one set ... genetic information contained in these chromosome sets helps determine ...
Cached Biology Technology:Global D-Amino Acids Industry 2Global D-Amino Acids Industry 3Global D-Amino Acids Industry 4Global D-Amino Acids Industry 5Global D-Amino Acids Industry 6Global D-Amino Acids Industry 7Global D-Amino Acids Industry 8Global D-Amino Acids Industry 9Global D-Amino Acids Industry 10Global D-Amino Acids Industry 11Global D-Amino Acids Industry 12Global D-Amino Acids Industry 13Global D-Amino Acids Industry 14Global D-Amino Acids Industry 15Global D-Amino Acids Industry 16Global Metabolomics Industry 2Global Metabolomics Industry 3Global Metabolomics Industry 4Global Metabolomics Industry 5Global Metabolomics Industry 6Global Metabolomics Industry 7Scientists create mammalian cells with single chromosome set 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... Our genetic information is stored in DNA, tiny strands ... of our bodies. To express this genetic data, our ... the instructions into proteins that perform tasks in our ... new type of RNA molecule. Unlike all other known ... RNA. Although circRNA molecules are abundant, little has been ...
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 23rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... based compounds, which are 8-mer LNA oligonucleotides, successfully inhibit ... a variety of diseases, including cancer, viral infections, cardiovascular ... affinity and target specificity of tiny LNA-based compounds enabled ... of tissues without off-target effects Tiny ...
... is a health problem that affects hundreds of ... billion every year in North America. Researchers from the ... Canada say they are gaining a deeper understanding of ... treatment using antibodies from llamas. "We have found ...
... NY) Researchers at Albert Einstein College of Medicine ... enzyme family found in humans and throughout the plant and ... Their findings suggest an entirely new strategy for treating conditions ... Sharp, Ph.D. , associate professor of physiology & biophysics ...
Cached Biology News:New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families 2New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families 3Researchers step closer to treatment of virulent hospital infection 2Enzyme can steer cells or possibly stop them in their tracks 2
Fast, sensitive quantitation of Mouse IgM concentration....
... 200 g of lyophilized peptide derived from ... acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptide ... of Cayman's EP1 receptor polyclonal antibody (Catalog ... conjunction with this antibody to block protein-antibody ...
... x 25 mm; approximately 1 mm thick, ... sections, sandblasted frosted writing ... markings will not rub off or wash off ... store at room temperature ...
Complete cell culture media with cytokines...
Biology Products: